JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future
Authors
Keywords
-
Journal
Biomolecules
Volume 10, Issue 7, Pages 1002
Publisher
MDPI AG
Online
2020-07-06
DOI
10.3390/biom10071002
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
- (2020) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis
- (2020) Pablo Olivera et al. GASTROENTEROLOGY
- The etiology of rheumatoid arthritis
- (2020) Hans Ulrich Scherer et al. JOURNAL OF AUTOIMMUNITY
- Cost-effectiveness analysis of treatment sequences containing tofacitinib for the treatment of rheumatoid arthritis in Spain
- (2020) F. Navarro et al. CLINICAL RHEUMATOLOGY
- The Effect of Renal Impairment on the Pharmacokinetics and Safety of Itacitinib
- (2020) Nithya Srinivas et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study
- (2020) Hideto Kameda et al. RHEUMATOLOGY
- Loss of JAK1 Drives Innate Immune Deficiency
- (2019) Agnieszka Witalisz-Siepracka et al. Frontiers in Immunology
- New alternative in the treatment of rheumatoid arthritis: clinical utility of baricitinib
- (2019) Paweł Kawalec et al. Therapeutics and Clinical Risk Management
- Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials
- (2019) Masayoshi Harigai et al. Modern Rheumatology
- JAK/STAT signaling in stem cells and regeneration: from Drosophila to vertebrates
- (2019) Salvador C. Herrera et al. DEVELOPMENT
- Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases
- (2019) Anniina T. Virtanen et al. BIODRUGS
- Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials
- (2019) Wenhui Xie et al. ANNALS OF THE RHEUMATIC DISEASES
- Tofacitinib Treatment is Associated with Modest and Reversible Increases in Serum Lipids in Patients with Ulcerative Colitis
- (2019) Bruce E. Sands et al. Clinical Gastroenterology and Hepatology
- Peficitinib: First Global Approval
- (2019) Anthony Markham et al. DRUGS
- Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study
- (2019) Josef S Smolen et al. LANCET
- Tofacitinib Treatment of Refractory Systemic Juvenile Idiopathic Arthritis
- (2019) Zhixiang Huang et al. PEDIATRICS
- Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response
- (2019) Roy M Fleischmann et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)
- (2019) Yoshiya Tanaka et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan
- (2019) Tsutomu Takeuchi et al. ANNALS OF THE RHEUMATIC DISEASES
- Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review
- (2019) Jehanya Jegatheeswaran et al. Immunotherapy
- Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy
- (2019) Mark C. Genovese et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy and safety of long-term baricitinib with and without methotrexate for the treatment of rheumatoid arthritis: experience with baricitinib monotherapy continuation or after switching from methotrexate monotherapy or baricitinib plus methotrexate
- (2019) Roy Fleischmann et al. ARTHRITIS CARE & RESEARCH
- Upadacitinib versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase 3, Double‐Blind, Randomized Controlled Trial
- (2019) Roy Fleischmann et al. Arthritis & Rheumatology
- Micrornas in rheumatoid arthritis: From pathogenesis to clinical impact
- (2019) Gerasimos Evangelatos et al. AUTOIMMUNITY REVIEWS
- A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA
- (2019) Elizabeth Wehler et al. PHARMACOECONOMICS
- Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent
- (2019) Alessia Alunno et al. Cells
- Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects with Normal and Impaired Renal Function
- (2019) Daisuke Miyatake et al. CLINICAL DRUG INVESTIGATION
- Changes in Serum Cytokines May Predict Therapeutic Efficacy of Tofacitinib in Rheumatoid Arthritis
- (2019) Yuxuan Li et al. MEDIATORS OF INFLAMMATION
- Evaluation of Clinical Cardiac Safety of Itacitinib, a JAK1 Inhibitor, in Healthy Participants
- (2019) Xiaohua Gong et al. Clinical Pharmacology in Drug Development
- Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers
- (2018) Kent J. Weinhold et al. CLINICAL IMMUNOLOGY
- Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment
- (2018) Jaehwan Kim et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial
- (2018) Mark C Genovese et al. LANCET
- Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial
- (2018) Gerd R Burmester et al. LANCET
- Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
- (2018) Lesley Uttley et al. PHARMACOECONOMICS
- Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
- (2018) Shijie Ren et al. PHARMACOECONOMICS
- JAK/STAT – Emerging Players in Metabolism
- (2018) David W. Dodington et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System
- (2018) Satoshi Kubo et al. Frontiers in Immunology
- An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective
- (2018) Lindsay Claxton et al. Journal of Managed Care & Specialty Pharmacy
- Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review
- (2018) Paul Emery et al. ADVANCES IN THERAPY
- Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study
- (2018) Tsutomu Takeuchi et al. ANNALS OF THE RHEUMATIC DISEASES
- Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors
- (2018) Fabiola Atzeni et al. Expert Review of Clinical Immunology
- Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
- (2018) Josef S. Smolen et al. JOURNAL OF RHEUMATOLOGY
- The molecular details of cytokine signalling via the JAK/STAT pathway
- (2018) Rhiannon Morris et al. PROTEIN SCIENCE
- OUP accepted manuscript
- (2018) RHEUMATOLOGY
- OUP accepted manuscript
- (2018) RHEUMATOLOGY
- The Jakinibs in systemic lupus erythematosus: progress and prospects
- (2018) Chi Chiu Mok EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Diagnosis and Management of Rheumatoid Arthritis
- (2018) Daniel Aletaha et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis
- (2018) Martina Morelli et al. Journal of Immunology Research
- Impact of tofacitinib treatment on human B-cells in vitro and in vivo
- (2017) Marta Rizzi et al. JOURNAL OF AUTOIMMUNITY
- Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor
- (2017) Fiona Elwood et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- JAK inhibitors in dermatology: The promise of a new drug class
- (2017) William Damsky et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial
- (2017) Roy Fleischmann et al. LANCET
- Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: A 52-week, randomized, single-blind, extension study
- (2017) Yoshiya Tanaka et al. Modern Rheumatology
- Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials
- (2017) Yoshiya Tanaka et al. Modern Rheumatology
- Therapeutic Potential of Targeting the Th17/Treg Axis in Autoimmune Disorders
- (2017) Patrizia Fasching et al. MOLECULES
- The emerging safety profile of JAK inhibitors in rheumatic disease
- (2017) Kevin L. Winthrop Nature Reviews Rheumatology
- Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
- (2017) Peter C. Taylor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study
- (2017) Nicolino Ruperto et al. Pediatric Rheumatology
- A Jak1/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro
- (2017) Kohei Murakami et al. PLoS One
- Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate
- (2017) A. J. Kivitz et al. Arthritis & Rheumatology
- Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials
- (2017) Frédéric Vanhoutte et al. Arthritis & Rheumatology
- Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis
- (2017) Mark C. Genovese et al. Arthritis & Rheumatology
- Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment
- (2017) Roy Fleischmann et al. Arthritis & Rheumatology
- Intestinal Dysbiosis and Rheumatoid Arthritis: A Link between Gut Microbiota and the Pathogenesis of Rheumatoid Arthritis
- (2017) Gabriel Horta-Baas et al. Journal of Immunology Research
- Canonical and Non-Canonical Aspects of JAK–STAT Signaling: Lessons from Interferons for Cytokine Responses
- (2017) Andrea Majoros et al. Frontiers in Immunology
- Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)
- (2016) A Kavanaugh et al. ANNALS OF THE RHEUMATIC DISEASES
- Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)
- (2016) R Westhovens et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings
- (2016) Mark C Genovese et al. ANNALS OF THE RHEUMATIC DISEASES
- Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
- (2016) Maxime Dougados et al. ANNALS OF THE RHEUMATIC DISEASES
- Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis
- (2016) Maria-Cecilia Vieira et al. CLINICAL THERAPEUTICS
- Janus kinase inhibitors for rheumatoid arthritis
- (2016) Kunihiro Yamaoka CURRENT OPINION IN CHEMICAL BIOLOGY
- Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies
- (2016) Roy Fleischmann et al. International Journal of Rheumatic Diseases
- Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study
- (2016) Y. Tanaka et al. JOURNAL OF RHEUMATOLOGY
- Baricitinib in Patients with Refractory Rheumatoid Arthritis
- (2016) Mark C. Genovese et al. NEW ENGLAND JOURNAL OF MEDICINE
- Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases
- (2016) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies
- (2016) Hendrik Schulze-Koops et al. RHEUMATOLOGY
- Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
- (2016) Mark C. Genovese et al. Arthritis & Rheumatology
- A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy
- (2016) Joel M. Kremer et al. Arthritis & Rheumatology
- An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States
- (2016) Lindsay Claxton et al. Journal of Managed Care & Specialty Pharmacy
- THU0178 Relationship Between NK Cell Count and Important Safety Events in Rheumatoid Arthritis Patients Treated with Tofacitinib
- (2015) R.F. van Vollenhoven et al. ANNALS OF THE RHEUMATIC DISEASES
- LB0001 Baricitinib, an Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and An Inadequate Response to CDMARD Therapy: Results of the Phase 3 RA-Build Study:
- (2015) M. Dougados et al. ANNALS OF THE RHEUMATIC DISEASES
- Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors
- (2015) W Gao et al. ANNALS OF THE RHEUMATIC DISEASES
- OP0029 Baricitinib, An Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-Beacon Study:
- (2015) M.C. Genovese et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study
- (2015) Tsutomu Takeuchi et al. ANNALS OF THE RHEUMATIC DISEASES
- Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme
- (2015) Jeffrey R Curtis et al. ANNALS OF THE RHEUMATIC DISEASES
- The Immunobiology of Interleukin-27
- (2015) Hiroki Yoshida et al. Annual Review of Immunology
- The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
- (2015) John J. O'Shea et al. Annual Review of Medicine
- Emerging EPO and EPO receptor regulators and signal transducers
- (2015) D. Kuhrt et al. BLOOD
- Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection
- (2015) Florence Namour et al. CLINICAL PHARMACOKINETICS
- Ocular Involvement in Systemic Autoimmune Diseases
- (2015) Elena Generali et al. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
- Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea
- (2015) Min-Young Lee et al. CLINICAL THERAPEUTICS
- Association of HLA-DRB1 Haplotypes With Rheumatoid Arthritis Severity, Mortality, and Treatment Response
- (2015) Sebastien Viatte et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases
- (2015) Luc J. Farmer et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeting JAK kinase in solid tumors: emerging opportunities and challenges
- (2015) M Buchert et al. ONCOGENE
- 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
- (2015) Jasvinder A. Singh et al. ARTHRITIS CARE & RESEARCH
- A Randomized, Double-Blind, Placebo-Controlled, Twelve-Week, Dose-Ranging Study of Decernotinib, an Oral Selective JAK-3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis
- (2015) Roy M. Fleischmann et al. Arthritis & Rheumatology
- VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis
- (2015) Mark C. Genovese et al. Arthritis & Rheumatology
- Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib
- (2015) Christina Charles-Schoeman et al. Arthritis & Rheumatology
- Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
- (2015) Mark C. Genovese et al. Arthritis & Rheumatology
- Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
- (2014) Edward C Keystone et al. ANNALS OF THE RHEUMATIC DISEASES
- The molecular regulation of Janus kinase (JAK) activation
- (2014) Jeffrey J. Babon et al. BIOCHEMICAL JOURNAL
- The Use of Biologic Therapies in the Treatment of Rheumatoid Arthritis
- (2014) Dashan Wang et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Leptin and its receptors
- (2014) Nobuhiro Wada et al. JOURNAL OF CHEMICAL NEUROANATOMY
- The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers
- (2014) Jack G. Shi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634
- (2014) Christel J. Menet et al. JOURNAL OF MEDICINAL CHEMISTRY
- Tofacitinib versus Methotrexate in Rheumatoid Arthritis
- (2014) Eun Bong Lee et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin-13-induced activation of signal transducer and activator of transcription 6 is mediated by an activation of Janus kinase 1 in cultured human bronchial smooth muscle cells
- (2014) Chiba Yoshihiko et al. Pharmacological Reports
- Pharmacoeconomic Analysis Tofacitinib Use in Rheumatoid Arthritis Treatment Scheme
- (2014) A. Kulikov et al. VALUE IN HEALTH
- Analysis of Infections and All-Cause Mortality in Phase II, Phase III, and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis
- (2014) Stanley Cohen et al. Arthritis & Rheumatology
- Systematic Review: Comparative Effectiveness and Harms of Disease-Modifying Medications for Rheumatoid Arthritis
- (2013) Katrina E. Donahue et al. ANNALS OF INTERNAL MEDICINE
- Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis
- (2013) Joel Kremer et al. ANNALS OF INTERNAL MEDICINE
- The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells
- (2013) Satoshi Kubo et al. ANNALS OF THE RHEUMATIC DISEASES
- Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study
- (2013) Désirée van der Heijde et al. ARTHRITIS AND RHEUMATISM
- Therapeutic Targeting of the JAK/STAT Pathway
- (2013) Saara Aittomäki et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Studies of Jak/STAT3 expression and signalling in psoriasis identifies STAT3-Ser727 phosphorylation as a modulator of transcriptional activity
- (2013) Rosa M. Andrés et al. EXPERIMENTAL DERMATOLOGY
- Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
- (2013) Cem Gabay et al. LANCET
- Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
- (2013) Gerd R Burmester et al. LANCET
- Activation of the NF-κB Pathway by the STAT3 Inhibitor JSI-124 in Human Glioblastoma Cells
- (2013) Braden C. McFarland et al. MOLECULAR CANCER RESEARCH
- Genetics of rheumatoid arthritis contributes to biology and drug discovery
- (2013) Yukinori Okada et al. NATURE
- Genetics and epigenetics of rheumatoid arthritis
- (2013) Sebastien Viatte et al. Nature Reviews Rheumatology
- Personality, Socio-Economic Status and Inflammation: Cross-Sectional, Population-Based Study
- (2013) Keith Millar et al. PLoS One
- The Microbiome in Infectious Disease and Inflammation
- (2012) Kenya Honda et al. Annual Review of Immunology
- The JAK-STAT Pathway at Twenty
- (2012) George R. Stark et al. IMMUNITY
- Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
- (2012) Roy Fleischmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
- (2012) Ronald F. van Vollenhoven et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prescribing practices in a US cohort of rheumatoid arthritis patients before and after publication of the American College of Rheumatology treatment recommendations
- (2011) Leslie R. Harrold et al. ARTHRITIS AND RHEUMATISM
- Use of Biologics in Rheumatoid Arthritis: Current and Emerging Paradigms of Care
- (2011) Jeffrey R. Curtis et al. CLINICAL THERAPEUTICS
- Interleukin-6 Protects Human Macrophages from Cellular Cholesterol Accumulation and Attenuates the Proinflammatory Response
- (2011) Eric Frisdal et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Juvenile idiopathic arthritis
- (2011) Berent Prakken et al. LANCET
- The Pathogenesis of Rheumatoid Arthritis
- (2011) Iain B. McInnes et al. NEW ENGLAND JOURNAL OF MEDICINE
- TNF activates calcium-nuclear factor of activated T cells (NFAT)c1 signaling pathways in human macrophages
- (2011) A. Yarilina et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Smoking, citrullination and genetic variability in the immunopathogenesis of rheumatoid arthritis
- (2011) Lars Klareskog et al. SEMINARS IN IMMUNOLOGY
- Structure and function of interleukin-22 and other members of the interleukin-10 family
- (2010) Daniela Barretto Barbosa Trivella et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Ethnogenetic heterogeneity of rheumatoid arthritis—implications for pathogenesis
- (2010) Yuta Kochi et al. Nature Reviews Rheumatology
- Thymic stromal lymphopoietin-mediated STAT5 phosphorylation via kinases JAK1 and JAK2 reveals a key difference from IL-7-induced signaling
- (2010) Y. Rochman et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Influence of gender on assessments of disease activity and function in early rheumatoid arthritis in relation to radiographic joint damage
- (2009) M Ahlmen et al. ANNALS OF THE RHEUMATIC DISEASES
- Cross-talk between calcineurin/NFAT and Jak/STAT signalling induces cardioprotective αB-crystallin gene expression in response to hypertrophic stimuli
- (2009) Irena Manukyan et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Expression of IL-24, an Activator of the JAK1/STAT3/SOCS3 Cascade, Is Enhanced in Inflammatory Bowel Disease
- (2009) A. Andoh et al. JOURNAL OF IMMUNOLOGY
- IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-γ are not
- (2009) Kerstin Wolk et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- The role of interleukin-17 in the pathogenesis of rheumatoid arthritis
- (2009) Sarah L. Gaffen Current Rheumatology Reports
- Structures and biological functions of IL-31 and IL-31 receptors
- (2008) Qing Zhang et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Paradigm shifts in the cell biology of STAT signaling
- (2008) Pravin B. Sehgal SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Canonical and non-canonical JAK–STAT signaling
- (2008) Willis X. Li TRENDS IN CELL BIOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started